"We wouldn't be betting $2.4 billion in cash unless we were optimistic" it would work, said Bristol-Myers Chief Executive James Cornelius
Results from this most recent trial are expected next year. Positive results could lead to FDA approval. The FDA has already designated fast track status for ipilimumab which helped get it quickly through clinical trials.
I am excited to see that there is a lot of buzz about this treatment, but only time will tell what if any effect this drug will have. There was another clinical trial that included this drug along with another immunotherapy agent that was in Phase III study. It had closed just about the time I was diagnosed with Stage IV melanoma. There are currently no other clinical trials that include ipilimumab that I am interested in.
More Information:
http://www.forbes.com/2009/07/23/bristol-myers-medarex-business-healthcare-cancer.html
No comments:
Post a Comment